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Abstract  
 
Through drinking water and food, millions of people worldwide are exposed to arsenic (As), 
which is a naturally occurring diabetogenic metalloid [13]. Inorganic arsenic (iAs) exposure may 
disrupt glucose homeostasis leading to type 2 diabetes (T2D), including: (i) insulin resistance 
due to inhibition of insulin signaling, (ii) inhibition of insulin secretion, and (iii) aberrant micro 
RNA expression and activity [1, 2, 13]. Arsenic methyltransferase (AS3MT) is the key enzyme 
in iAs detoxification pathway that determines disease outcome [3]. Polymorphisms in AS3MT is 
the single most important genetic factor affecting iAs metabolism and susceptibility to adverse 
effects of iAs exposure, including diabetes. This study aims to examine the relationship between 
As3mt polymorphism and the adverse outcomes of iAs exposure in two Collaborative Cross (CC) 
mouse strains, CC021/Unc (CC021) and CC027/TauUnc (CC027), with different genetic 
backgrounds. Metabolic phenotype and susceptibility to adverse effects of iAs exposure are 
hypothesized to differ in CC021 and CC027 due to the differences in their hepatic As3mt 
expression and iAs metabolism (in liver). The metabolic/diabetic phenotype and iAs metabolism 
were assessed in both strains after 12 weeks of exposure to 100 ppb or 50 ppm iAs (sodium 
arsenite) in drinking water. The differences we observed between phenotypes of CC021 and 
CC027 mice were determined mainly by the genetic backgrounds of these strains and only to 
smaller extent by iAs exposure. Differences due to iAs exposure were found in weight gain, 
glycemia and insulin response to i.p. glucose injection, as well as in total As level in urine and in 
the percentage of total As represented by iAs. In future studies, we aim to identify other genes 
that underlie the susceptibility to iAs-associated T2D and establish a better mouse model in 
which As3mt expression and iAs metabolism resemble those in humans. 
 
Aims and Hypothesis 
The overall hypothesis of the study is that metabolic phenotype and susceptibility to adverse 
effects of iAs exposure differ between CC021 and CC027 mice due to the differences in their 
hepatic As3mt expression and iAs metabolism in liver. 
 
Aim 1. Evaluation of the Diabetogenic Effects of iAs Exposure  
Body weight, body composition, fasting blood glucose and insulin levels, glucose tolerance, 
insulin resistance and -cell function were measured in CC mice chronically exposed to iAs.  
Hypothesis 1: Metabolic phenotypes of the CC strains exposed to iAs will differ.  
 
Aim 2. Evaluation of the iAs Metabolism 
The proportions and concentrations of iAs and its methylated (MAs) and dimethylated (DMAs) 
metabolites were measured in the urine of the CC mice after chronic exposures to iAs. 
Hypothesis 2: iAs metabolism will differ in CC021 and CC027 mouse strains.  
 
Introduction 
Arsenic (As) is a naturally occurring toxic metalloid. Over 100 million people worldwide drink 
water with inorganic As (iAs) levels higher than the US EPA and WHO maximum level of 10 μg 
As/L [4, 5]. More people may be exposed to unsafe levels of iAs in foods [6-10].  
 
The International Agency for Research on Cancer defines iAs as a Group-I human carcinogen 
[11]. Exposure to iAs is also associated with a wide array of non-cancer effects such as 
neurological impairment, respiratory disease, cardiovascular disease, and diabetes [12]. In 2011, 
the National Toxicology Program Workshop on the environmental diabetogens and obesogens 
found sufficient evidence for the relationship between moderate to high levels of exposure to iAs 
in drinking water (>150 ppb; i.e., >150 µg As/L) and diabetes [13]. Two recent meta-analyses 
that included studies at lower exposure levels found pooled relative risks of developing diabetes 
in the presence of iAs exposure equal to 1.7 and 1.23 [14,15].  
According to previous studies, the insulin producing pancreatic β-cells are among the targets for 
iAs exposure [1, 16]. The inhibition of glucose-stimulated insulin secretion (GSIS) by low 
concentrations of the methylated metabolites of iAs may be the key mechanism of iAs-induced 
diabetes [1]. Trivalent arsenicals interfere with mechanisms regulating packaging of the insulin 
transport vesicles or with translocation of these vesicles to the plasma membrane [1]. Defects in 
insulin secretion could also be associated with aberrant microRNA expression and activity [2]. In 
addition, micromolar concentrations of inorganic trivalent arsenite (iAsIII) or its methylated 
trivalent metabolites, methylarsonite (MAsIII) and dimethylarsinite (DMAsIII), inhibit the 
insulin-activated signal transduction pathway, resulting in insulin resistance and impaired 
glucose metabolism in adipocytes and hepatocytes [13, 17, 18]. 
 
Arsenic methyltransferase (AS3MT) is the key enzyme in the pathway for iAs metabolism [3]. 
Methylation of inorganic As determines the efficiency of iAs detoxification and the disease risk. 
AS3MT converts iAs to mono- and dimethylated metabolites (MAs, DMAs) that are excreted 
mainly in urine. The efficiency of iAs methylation can be estimated using the proportions of As 
metabolites in urine. A low DMAs/MAs ratio and high percentage of total urinary As 
represented by MAs (%MAs) are indicators of an inefficient iAs methylation and known risk 
factors for cancers and cardiovascular diseases associated with iAs exposure [3, 19-23]. 
However, the methylated trivalent metabolites formed in this pathway are potent inhibitors of 
processes that regulate glucose metabolism, including insulin secretion by pancreatic β-cells and 
insulin signaling in the liver and peripheral tissues [1]. Thus, in a counter-intuitive manner, while 
essential for total body clearance, the metabolism/methylation of iAs generates metabolites that 
likely contribute to the diabetogenic effects of iAs exposure.  
Many population studies have examined the association between genetic polymorphism and the 
pattern of iAs metabolism. Although polymorphisms in several genes that are thought to regulate 
various steps in iAs metabolism have been linked with differences in the capacity to methylate 
iAs and in iAs toxicity, polymorphisms in AS3MT are the single most important genetic factor 
affecting iAs metabolism and susceptibility to adverse effects of iAs exposure, including 
diabetes, in population studies [24-29]. Notably, results of laboratory studies using genetically 
modified cells and mice, including our published and preliminary studies, support the critical 
role for As3mt in iAs metabolism. [19, 42]  
In short, according to previous studies, iAs exposure may disrupt glucose homeostasis leading to 
T2D, including: (i) insulin resistance due to inhibition of insulin signaling, (ii) inhibition of 
insulin secretion, and (iii) aberrant micro RNA expression and activity [1, 2, 13]. AS3MT is the 
key enzyme in As metabolism while its polymorphisms are the most important genetic factor 
affecting susceptibility to As-related diabetes [3]. However, the relationship between As3mt 
polymorphism and the adverse outcomes of iAs exposure has never been systematically 
examined in animal models.  
The goal of the present study was to characterize the effects of iAs exposure on metabolic 
phenotypes of mice from two Collaborative Cross (CC) strains, CC021/Unc (CC021) and 
CC027/TauUnc (CC027), that have different As3mt haplotypes (non-obese diabetic 
(NOD)/ShiLtJ and Watkins Star Line B (WSB)/EiJ, respectively) and different SNPs in As3mt 
gene. CC strains are products of an eight-way funnel breeding design involving eight genetically 
diverse JAX® mice founder strains: A/J (000646), C57BL/6J (000664), 129S1/SvImJ (002448) 
NOD/ShiLtJ (001976)  NZO/HiLtJ (002105), CAST/EiJ (000928), PWK/PhJ (003715), and 
WSB/EiJ (001145) [30]. Preliminary studies carried out in our laboratory showed that the hepatic 
expression of As3mt (Fig. 1) and patterns of iAs metabolism in these two strains, specifically the 
proportions of total As present as iAs (%iAs) and DMAs (%DMAs) in the liver (Fig. 2), are also 
significantly different. 
 
 
Figure 1: Baseline expression of As3mt in livers of male CC021 and CC027 mice.  (N=4) 
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 Figure 2: Proportions of As species in livers of male CC021 and CC027 mice. Mice were 
exposed to 50 ppm iAs (arsenite) for 2 weeks. (N=5). Total As (Mean ±SD): 1342 ±652 ng/g 
(CC021) and 1609 ±317 ng/g (CC027). 
The current project expands our knowledge of the mechanisms of iAs related diseases, 
specifically diabetes, and the role of As3mt genotype as factor that modifies the disease risk. 
This project also has a potential to move forward the entire field of iAs toxicology by providing 
novel mouse models for laboratory studies, and to contribute significantly to risk assessment of 
iAs-associated diseases based on genetic susceptibility.  
Methods 
Mice  
All procedures involving mice were approved by the University of North Carolina (UNC) 
Institutional Animal Care and Use Committee. Four-week old male CC021 and CC027 mice 
were obtained from the UNC Systems Genetics Core Facility and allowed to acclimate for 2 
weeks. During this time, mice drank deionized water (DIW) and had unlimited access to a semi-
purified AIN-93G diet. Mice were housed under controlled conditions with 12-h light/ dark cycle 
at 22 ± 1 °C and 50 ± 10% relative humidity (2–5 mice per cage).  
 
Exposure 
After acclimatization, mice from both strains were exposed to 100 ppb or 50 ppm iAs (sodium 
arsenite NaAsO2, ≥99% pure; Sigma-Aldrich, St. Louis, MO, USA) in drinking water for 12 
weeks; control mice continued drinking DIW. Water with sodium arsenite was prepared weekly 
to minimize oxidation of iAsIII to iAsV. 
 
Metabolic Phenotype Assessment 
Body weights and water and food consumption were monitored bi-weekly during exposure. 
Body composition, fasting blood glucose and insulin levels, and glucose tolerance were 
examined at the end of exposure. Magnetic resonance imaging (MRI) (EchoMRI 3-in-1 analyzer, 
Echo Medical Systems, Houston, TX, USA and Labmaster version 3.2.2. Software) was used to 
determine body composition, specifically grams of fat mass and grams of lean mass. For glucose 
and insulin analysis, mice were fasted for 6 hours. Fasting blood glucose (FBG) levels were 
measured in blood collected from tail cuts using OneTouch Ultra 2 glucometer (LifeScan, 
Milpitas, CA, USA) and OneTouch Ultra Blue test strips. Fasted mice were then injected i.p. 
with 2 g/ kg b.w. of D-glucose (Sigma-Aldrich) dissolved in Dulbecco’s phosphate-buffered 
saline (Mediatech, Manassas, VA, USA). Glucose levels were measured in blood collected by 
tail bleeds 15 min post-injection. Plasma insulin was measured in fasting and 15 min post-
injection plasma using Ultra Sensitive Mouse Insulin ELISA Kit according to the manufacturer’s 
instructions (Crystal Chem, Elk Grove Village, IL, USA). 
HOMA-IR and HOMA-B were calculated from fasting blood glucose and plasma insulin values 
using the following formulas:  
• HOMA-IR = 
𝐹𝑎𝑠𝑡𝑖𝑛𝑔 𝐵𝑙𝑜𝑜𝑑 𝐺𝑢𝑐𝑜𝑠𝑒 (
𝑚𝑔
𝑑𝐿
)×𝐹𝑎𝑠𝑡𝑖𝑛𝑔 𝑃𝑙𝑎𝑠𝑚𝑎 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 (
𝜇𝑈
𝑚𝐿
)
405
  [44] 
• HOMA-B = 
360×𝐹𝑎𝑠𝑡𝑖𝑛𝑔 𝑃𝑙𝑎𝑠𝑚𝑎 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 (
𝜇𝑈
𝑚𝐿
)
𝐹𝑎𝑠𝑡𝑖𝑛𝑔 𝐵𝑙𝑜𝑜𝑑 𝐺𝑙𝑢𝑐𝑜𝑠𝑒 (
𝑚𝑔
𝑑𝐿
)−63
% [45] 
𝐹𝑎𝑠𝑡𝑖𝑛𝑔 𝑃𝑙𝑎𝑠𝑚𝑎 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 (
𝜇𝑈
𝑚𝐿
)=
𝐹𝑎𝑠𝑡𝑖𝑛𝑔 𝑃𝑙𝑎𝑠𝑚𝑎 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 (
𝑛𝑔
𝑚𝐿
)
0.0347 (
𝑛𝑔
𝜇𝑈
)
 
Analysis of As species in urine 
Spot urine samples were collected at the end of the exposure. The concentrations of iAs, MAs, 
and DMAs were measured in spot urine samples using hydride generation-atomic absorption 
spectrometry coupled with a cryotrap [32, 33]. The proportions of iAs and its methylated 
metabolites in urine (%iAs, %MAs, and %DMAs) were used to assess differences in methylation 
capacity of mice in both strains. 
 
Statistical Analysis 
Data were analyzed using ANOVA and Tukey-Kramer multiple comparisons test.  Differences 
with P<0.05 were regarded as statistically significant. Mean ±SE were calculated and graphed 
for each outcome. 
 
Results 
Body weights were measured bi-weekly and weight gain was calculated for each mouse as a 
difference between body weight at the end of the exposure and body weight at the beginning of 
the exposure. 
  
 
 Figure 3: Average final body weight (A), weight gain (B), %body fat (C) and %lean mass (D) of 
CC021 and CC027 mice exposed to 100 ppb or 50 ppm iAs and the control mice (0 ppm).  
Mean ±SE. * Statistically significant differences (P<0.05) using ANOVA and Tukey-Kramer 
multiple comparisons test.   
 
No statistically significant difference in body weight at the end of the exposure were seen 
between the two strains or between different exposure levels (Fig. 3A). However, CC021 mice 
tended to have higher body weight while mice exposed to 50 ppm iAs in both strains tended to 
have lower body weight (Fig. 3A). Percent weight gain decreased significantly and in a dose-
dependent manner in CC021, but not CC027 mice (Fig. 3B). CC021 mice, both iAs-exposed and 
controls, had significantly higher %fat mass than CC027 mice (Fig. 3C). CC027 mice had 
higher %lean mass than CC021 mice, but this difference was statistically significant only in mice 
exposed to 50 ppm iAs (Fig. 3D). Exposure to 100 ppb iAs tended to reduce %lean mass while 
exposure to 50 ppm increased %lean mass in both strains (Fig. 3D), but these effects were not 
statistically significant. Exposure to 100 ppb iAs tended to increase body weight, percent weight 
gain and %fat mass in CC027 mice but not in CC021 mice.  
 Figure 4: Blood glucose levels after fasting (A), 15 min after i.p. glucose injection (B), and the 
difference (change) between fasting and 15-min glucose levels (C).  
Mean ±SE. *Statistically significant differences (P<0.05) using ANOVA and Tukey-Kramer 
multiple comparisons test.   
CC027 mice exposed to 100 ppb iAs had higher blood glucose after 6-hour fasting and 15 min 
after i.p. glucose injection, and higher blood glucose change between fasting and 15-min glucose 
levels than CC021 mice (Fig. 4A, 4B, 4C). Effects of iAs exposure were relatively minor and 
were statistically significant only among CC027 mice. Here, mice exposed to 100 ppb iAs had 
significantly higher blood glucose levels 15 min after i.p. glucose injection than corresponding 
controls (Fig. 4A). A similar difference between control and 100 ppb mice was observed in the 
difference between fasting and 15-min glucose levels, but it was not statistically significant (Fig. 
4C). In addition, CC027 mice exposed to 50 ppm iAs had higher blood glucose levels after 6-
hour fasting than CC021 mice exposed to 50 ppm iAs (Fig. 4A). CC027 control mice had higher 
blood glucose levels 15 min after i.p. glucose injection than CC021 control mice (Fig. 4B).  
 
 
 Figure 5: Plasma insulin levels after fasting (A) and 15 min after i.p. glucose injection (B), and 
the difference (change) in insulin levels between fasting and 15-min after glucose injection (C).  
Mean ±SE. *Statistically significant differences (P<0.05) using ANOVA and Tukey-Kramer 
multiple comparisons test.   
 
 CC021 mice, both iAs-exposed and controls, had higher plasma insulin levels after 6-hour 
fasting and 15 min after i.p. glucose injection than their CC027 counterparts. (Fig. 5A, 5B) 
Insulin response to i.p. glucose injection differed between the strains; however, this difference 
was not statistically significant (Fig. 5C). Fasting plasma insulin level tended to decrease in a 
dose dependent manner in CC021(Fig. 5A). 100 ppb iAs exposure tended to increase fasting 
plasma insulin level in CC027 and 15 min plasma insulin level in CC021 (Fig. 5A, 5B). 
 Figure 6: Insulin resistance (HOMA-IR) (A) and β-cell function (HOMA-B) (B).  
*Statistically significant differences (P<0.05) using ANOVA and Tukey-Kramer multiple 
comparisons test.   
 
CC021 mice (with NOD background), both iAs-exposed and controls, were more insulin 
resistant (Fig. 6A, 6B) than their CC027 counterparts. HOMA-IR decreased in a dose dependent 
manner in CC021although the differences between iAs-exposed and control mice were not 
statistically significant (Fig. 6A). 100 ppb iAs exposure tended to increase HOMA-IR in CC027 
and HOMA-B in CC021 (Fig. 6A).  
 Figure 7: Proportions of As species in urine: %iAs (A) and %DMAs (B). Mean ±SE. TAs = sum 
of As species. *Statistically significant differences (P<0.05) using ANOVA and Tukey-Kramer 
multiple comparisons test. 
 
Relatively small differences were found between the strains in As profiles in urine. Total As 
and %iAs were consistently higher in urine of CC021 as compared to CC027mice, both iAs-
exposed and controls, but these differences were not statistically significant. Exposure to iAs 
significantly decreased %iAs and increased %DMA in urine of both strains (Fig. 7A, 7B). MAs 
concentrations were at or below detection limit in most spot urine samples.  
 
Discussion  
Laboratory mice with varied genetic backgrounds have been extensively used in laboratory 
studies examining adverse effects of iAs exposure. However, it has been well documented that 
iAs methylation and excretion in mice is more efficient than in humans [19, 20], which likely 
explains the differences between these species in the responses to iAs exposure [34-36]. For 
instance, in all human populations studies to date, MAs and DMAs represented 10-20% and 60-
70% of total urinary As, respectively, with iAs accounting for 10-30% [19, 20].  In contrast, 
urine of mice exposed to iAs in published studies contains more than 80% of DMAs and only 
traces of MAs, suggesting a more efficient conversion of MAs to DMAs [19, 20].  Thus, a better 
animal model is needed in which iAs metabolism would resemble the human metabolism, and in 
which the effects of iAs exposure found in humans can be reproduced. Strong evidence suggests 
that the differences in the AS3MT genotypes are in part responsible for the differences in 
efficiency of iAs metabolism and in susceptibility to adverse effects of iAs exposure among 
humans and between mice and humans. This observation provided rationale for the present 
study. The goal of this study was to compare effects of iAs exposure on glucose homeostasis 
between 2 CC mouse strains that differ in As3mt genotype and demonstrate differences in the 
disposition of iAs and its metabolites in the liver. 
 
The causality of the association between iAs exposure and T2D is supported by prospective data 
from human cohorts and by results of laboratory studies suggesting that iAs and its metabolites 
impair mechanisms that regulate glucose homeostasis and are linked to T2D development [1, 16, 
37-41]. Results of previous and preliminary studies point to three mechanisms underlying the 
diabetogenic effects of exposure to iAs, including (i) insulin resistance due to inhibition of 
insulin signaling, (ii) inhibition of insulin secretion, and (iii) aberrant micro RNA expression and 
activity [1, 2, 13]. 
We have previously shown that urine and livers of control mice that drank only deionized water 
and were fed a regular grain-based diet (pelleted 2920X Teklad rodent chow, Envigo, Madison, 
WI, USA) contained relatively high levels of As, suggesting that these mice were exposed to As 
from diet [42]. When designing the present study, we included a two-week acclimatization 
period to allow for clearance of As to which the mice were exposed when fed a regular grain-
based diet before delivery to UNC. The methods we used for metabolic phenotype, including 
measures of fasting blood glucose and insulin, are widely utilized in diagnosis of diabetes in 
human patients and are good approximates of the diabetogenic effect of iAs exposure in mice 
[40, 43]. A simplified glucose tolerance test we used in this study was to assess the physiological 
response of mice to a glucose challenge, specifically blood glucose and plasma insulin levels at 
15 minutes after injection. The homeostasis model assessments HOMA-IR and HOMA-B, based 
on fasting glucose and insulin measures, have been validated and widely applied for quantifying 
insulin resistance and β-cell function in clinical setting, and are used here as proxies of these 
measure in mice [31]. 
The CC strains for this study were chosen based on results of our recent study that examined 
differences in iAs metabolism among male mice from 12 CC strains. CC21 mice had As3mt 
haplotypes from NOD founder strain while CC27 mice had As3mt haplotypes from WSB 
founder strain. However, their metabolic phenotype was more influenced by the overall genetic 
background. CC21 mice had lower percentage (7.16%) of NOD founder contribution in the 
overall genetic background that CC27 mice (18.32%) [46]. The NOD/ShiLtJ founder strain 
(commonly called NOD) is a polygenic model for autoimmune type 1 diabetes, characterized by 
hyperglycemia and insulitis [30].  
 
CC027 mice exposed to 100 ppb iAs had higher blood glucose after 6-hour fasting and 15 min 
after i.p. glucose injection, and higher blood glucose change between fasting and 15-min glucose 
levels than CC021 mice (Fig. 4A, 4B, 4C). CC027 mice exposed to 50 ppm iAs had higher blood 
glucose levels after 6-hour fasting than CC021 mice exposed to 50 ppm iAs (Fig. 4A). CC027 
control mice had higher blood glucose levels 15 min after i.p. glucose injection than CC021 
control mice (Fig. 4B).  
 
Defects in antigen presentation, T lymphocyte repertoire, natural killer cell function, macrophage 
cytokine production, wound healing, and C5 complement characterize immune phenotypes in the 
NOD background [30]. Insulitis is a leukocytic infiltration of the pancreatic islets and should be 
characterized by decreased β-cell mass and insulin secretion [30]. According to our results, 
CC027 mice, both iAs-exposed and controls, had lower plasma insulin levels after 6-hour fasting 
and 15 min after i.p. glucose injection than CC021 mice (Fig. 5A, 5B). CC027 mice exposed to 
100 ppb and 50 ppm iAs in drinking water had negative insulin change after glucose challenge 
(Fig. 5C). Lower plasma insulin level and negative insulin change in response to glucose 
challenge in CC027 probably represents decreased β-cell function and insulin secretion while 
exposure to iAs might deteriorate insulitis. 
 
The mechanism of developing insulitis in CC021 is unclear for now. According to previous 
study, micromolar concentrations of inorganic trivalent arsenite (iAsIII) or its methylated 
trivalent metabolites, methylarsonite (MAsIII) and dimethylarsinite (DMAsIII) inhibit the 
insulin-activated signal transduction pathway, resulting in insulin resistance in adipocytes and 
hepatocytes [13, 17, 18]. CC021 mice, both iAs-exposed and controls, had significantly 
higher %fat mass (Fig. 3C) and were more insulin resistant (Fig. 5, 6) than their CC027 
counterparts probably due to higher %fat mass. Insulin resistance could cause a long-term 
overstimulation of β-cells which leads to inflammation and autoimmune attack on β-cells. Insulin 
resistance and lower insulin secretion could together induce diabetes.  
 
Most of the phenotypic differences between the two strains were dependent on genetic 
background and independent of iAs exposure. Strain differences were pronounced in body 
composition (Fig. 3C, 3D), blood glucose (Fig. 4), plasma insulin (Fig. 5A, 5B) and insulin 
resistance (Fig. 6). iAs exposure had mostly minor effects on phenotype of mice in either strain. 
Dose dependent effects on the proportions of As species were seen in the urine of both 
strains: %iAs decreased and %DMA increased with increasing exposure level (Fig. 7). This is in 
contrast with data from human cohorts where %DMAs has been found to decrease with 
increasing exposure [22]. The differences between the strain in %iAs and %DMAs in urine, 
although consistent across the exposures, were not statistically significant for the given N 
numbers (Fig. 7). Strain-specific differences in responses to iAs exposure were also found in 
weight gain (Fig. 3B), 15-min blood glucose (Fig. 4B), and in insulin response to i.p. glucose 
injection (Fig. 5C). These differences support our hypothesis that metabolic phenotype and 
susceptibility to adverse effects of iAs exposure would differ in CC021 and CC027 and may be 
linked to the differences in their hepatic As3mt expression and iAs metabolism in the liver.  
 
However, the fact that most of the differences between these 2 strains were independent of iAs 
exposure suggests that the phenotypes of CC021 and CC027 mice exposed to iAs are determined 
primarily by their broader genetic backgrounds rather than by As3mt polymorphism and 
expression in the liver, or by the differences in iAs metabolism. Notably, the proportions of As 
species in urine of both strains were consistent with those reported in previous mouse studies and 
differed from the proportions found in human urine [19, 20]. Thus, neither CC021 nor CC027 is 
an ideal model to study metabolism of iAs or adverse effects associated with iAs exposure in 
humans. 
 
Although the polymorphisms in AS3MT have been shown to play a critical role in the efficiency 
of iAs metabolism in population and laboratory studies, other genes that may be involved in iAs 
detoxification or the regulation of glucose homeostasis are likely to contribute to T2D risk in 
individuals exposed to iAs [24-29]. In order to reduce variables in background genes and to 
isolate the effects of differences in genes affecting iAs metabolism in future studies, we need to 
improve our knowledge of these genes. In the next project, we will use the complementary 
resources of the Collaborative Cross (CC) and Diverse Outbred (DO) mouse populations to 
identify genes that underlie the susceptibility to iAs-associated T2D and are linked to specific 
diabetic phenotypes. We are also in the process of creating a humanized mouse strain. Here, we 
created embryonic stem cells, which express human AS3MT through syntenic replacement of 
mouse Borcs7/As3mt locus with the human locus. These humanized embryonic stem cells were 
injected into blastocysts to create mice expressing human AS3MT. We hypothesize that AS3MT 
expression in tissues and the pattern of iAs metabolism, and possibly the responses to iAs 
exposure in the humanized mice will resemble those described in human populations. 
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